Alnylam (ALNY) Reports Q3 Earnings: What Key Metrics Have to Say

Alnylam Pharmaceuticals (ALNY) reported $500.92 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 33.3%. EPS of -$0.50 for the same period compares to $1.15 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $529.34 million, representing a surprise of -5.37%. The company has not delivered EPS surprise, with the consensus EPS estimate being -$0.50.While investors closely watch year-over-year changes in headline numbers -- revenue and ea ...